mTORC inhibitors as broad-spectrum therapeutics for age-related diseases
Chronological age represents the greatest risk factor for many life-threatening diseases, including neurodegeneration, cancer, and cardiovascular disease; ageing also increases susceptibility to infectious disease. Current efforts to tackle individual diseases may have little impact on the overall h...
| Main Authors: | , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
MDPI
2018
|
| _version_ | 1797095666346885120 |
|---|---|
| author | Walters, H Cox, L |
| author_facet | Walters, H Cox, L |
| author_sort | Walters, H |
| collection | OXFORD |
| description | Chronological age represents the greatest risk factor for many life-threatening diseases, including neurodegeneration, cancer, and cardiovascular disease; ageing also increases susceptibility to infectious disease. Current efforts to tackle individual diseases may have little impact on the overall healthspan of older individuals, who would still be vulnerable to other age-related pathologies. However, recent progress in ageing research has highlighted the accumulation of senescent cells with chronological age as a probable underlying cause of pathological ageing. Cellular senescence is an essentially irreversible proliferation arrest mechanism that has important roles in development, wound healing, and preventing cancer, but it may limit tissue function and cause widespread inflammation with age. The serine/threonine kinase mTOR (mechanistic target of rapamycin) is a regulatory nexus that is heavily implicated in both ageing and senescence. Excitingly, a growing body of research has highlighted rapamycin and other mTOR inhibitors as promising treatments for a broad spectrum of age-related pathologies, including neurodegeneration, cancer, immunosenescence, osteoporosis, rheumatoid arthritis, age-related blindness, diabetic nephropathy, muscular dystrophy, and cardiovascular disease. In this review, we assess the use of mTOR inhibitors to treat age-related pathologies, discuss possible molecular mechanisms of action where evidence is available, and consider strategies to minimize undesirable side effects. We also emphasize the urgent need for reliable, non-invasive biomarkers of senescence and biological ageing to better monitor the efficacy of any healthy ageing therapy. |
| first_indexed | 2024-03-07T04:31:07Z |
| format | Journal article |
| id | oxford-uuid:ce5b8da7-39ff-472d-9a9f-559fe78fc26f |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:31:07Z |
| publishDate | 2018 |
| publisher | MDPI |
| record_format | dspace |
| spelling | oxford-uuid:ce5b8da7-39ff-472d-9a9f-559fe78fc26f2022-03-27T07:35:02ZmTORC inhibitors as broad-spectrum therapeutics for age-related diseasesJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ce5b8da7-39ff-472d-9a9f-559fe78fc26fEnglishSymplectic Elements at OxfordMDPI2018Walters, HCox, LChronological age represents the greatest risk factor for many life-threatening diseases, including neurodegeneration, cancer, and cardiovascular disease; ageing also increases susceptibility to infectious disease. Current efforts to tackle individual diseases may have little impact on the overall healthspan of older individuals, who would still be vulnerable to other age-related pathologies. However, recent progress in ageing research has highlighted the accumulation of senescent cells with chronological age as a probable underlying cause of pathological ageing. Cellular senescence is an essentially irreversible proliferation arrest mechanism that has important roles in development, wound healing, and preventing cancer, but it may limit tissue function and cause widespread inflammation with age. The serine/threonine kinase mTOR (mechanistic target of rapamycin) is a regulatory nexus that is heavily implicated in both ageing and senescence. Excitingly, a growing body of research has highlighted rapamycin and other mTOR inhibitors as promising treatments for a broad spectrum of age-related pathologies, including neurodegeneration, cancer, immunosenescence, osteoporosis, rheumatoid arthritis, age-related blindness, diabetic nephropathy, muscular dystrophy, and cardiovascular disease. In this review, we assess the use of mTOR inhibitors to treat age-related pathologies, discuss possible molecular mechanisms of action where evidence is available, and consider strategies to minimize undesirable side effects. We also emphasize the urgent need for reliable, non-invasive biomarkers of senescence and biological ageing to better monitor the efficacy of any healthy ageing therapy. |
| spellingShingle | Walters, H Cox, L mTORC inhibitors as broad-spectrum therapeutics for age-related diseases |
| title | mTORC inhibitors as broad-spectrum therapeutics for age-related diseases |
| title_full | mTORC inhibitors as broad-spectrum therapeutics for age-related diseases |
| title_fullStr | mTORC inhibitors as broad-spectrum therapeutics for age-related diseases |
| title_full_unstemmed | mTORC inhibitors as broad-spectrum therapeutics for age-related diseases |
| title_short | mTORC inhibitors as broad-spectrum therapeutics for age-related diseases |
| title_sort | mtorc inhibitors as broad spectrum therapeutics for age related diseases |
| work_keys_str_mv | AT waltersh mtorcinhibitorsasbroadspectrumtherapeuticsforagerelateddiseases AT coxl mtorcinhibitorsasbroadspectrumtherapeuticsforagerelateddiseases |